Search

Summary Background Ethiopia reported the first case of COVID-19 on 13th March, 2020 with community transmission ensuing by mid-May. A national, population-based serosurvey against anti-SARS-CoV-2 IgG was conducted to measure the prevalence of prior COVID-19 infections and better approximate the burden across major towns in Ethiopia. Methods We conducted a cross-sectional, population-based serosurvey from June 24 to July 8, 2020 in 14 major urban areas. Two-stage cluster sampling was used to randomly select enumeration areas and households. All persons aged ≥15 years were enrolled. Serum samples were tested by Abbott™ ARCHITECT™ assay for SARS-CoV-2 IgG antibodies. National COVID-19 surveillance data on the median date of the serosurvey is analyzed for comparison. Findings Adjusted seroprevalence was 3.5% (95% CI: 3.2%-3.8%) after controlling for age, sex and test kit performance. Males (3.7%) and females (3.3%) were nearly equally infected, while middle-aged adults '40-65 years' had the highest (4.0%) prevalence. Gambella (7.5%), Dire Dawa (6.2%) and Jigjiga (6.1%) were the most affected towns. About 6.7% and 8.0% of seropositives had symptoms and chronic underlying illness, respectively. A surveillance system had identified 4,416 RT-PCR confirmed cases in Addis Ababa. Interpretation This serosurvey shows that a majority of urban Ethiopians remain uninfected with SARS-CoV-2. Most anti-SARS-CoV-2 IgG positive cases were asymptomatic with no underlying illness, keeping case detection to a minimum.

Introduction Rates of full childhood immunization in Ethiopia are well below the WHO global goal of 90% coverage by 2020. This study explores associations between sociodemographic characteristics and healthcare services utilization with experiences of not receiving a vaccine in Ethiopia. Methods This analysis uses data from Ethiopia’s 2012 Expanded Program on Immunization Coverage Survey. The relationships between explanatory variables, including sociodemographic and healthcare utilization factors, and various reasons a child was not vaccinated were assessed with Rao-Scott chi-square tests. Multivariable logistic regression analyses examined significant predictors of these experiences. Results The sample includes the caregivers of 2,722 children. Experiences of not receiving a vaccine were characterized overall and by type of experience: whether a caregiver ever refused vaccination for their child (2.9%), ever decided to not take their child to a health center for vaccination (3.6%), and ever went to a health facility for vaccination but child was not vaccinated (12.0%). Region of residence, possession of a vaccination card, and the setting of the child’s last routine vaccination were predictors of not receiving a vaccine. Caregivers reported negative perceptions of vaccines were among their reasons for refusing a vaccine or declining to take their child to a health facility for vaccination. Conclusion Prior experiences with health facilities, such as where a child received their last routine vaccine, play a key role in future vaccination. Vaccine receipt at an outreach event is associated with not bringing a child to a health facility for vaccination, which may indicate an unwillingness to visit or difficulty accessing health centers. Further, negative perceptions of vaccines may result in vaccine refusal or delay. Findings of this study provide public health officials with a better understanding of factors related to vaccination experiences and can inform development of interventions that will improve childhood vaccination rates in Ethiopia.

Objective: To assess the prevalence and intensity of intestinal schistosomiasis and soil transmitted helminthiasis among primary school children in Gorgora, Northwest Ethiopia. Methods: A cross-sectional epidemiological study was carried out in Gorgora primary school in Northwest Ethiopia from November to December 201 0. Stool sample was collected from 326 children (170 male and 156 female) and examined by Kato-Katz technique for intestinal schistosomiasis and soil transmitted helminth infection. Results: A total of 120 children (56 males and 64 females) were positive for single or multiple parasitic infection. Four helminth parasite species were identified and the most prevalent was Ascaris lumbricoides (A. lumbricoides) (16.60%), followed by Schistosoma mansoni (S. mansoni) (10.10%), hookworm (5.50%) and Trichuris trichiura (T. trichiura) (4.60%). Furthermore, 1.84%, 2.76% and 2.45% of the study participants were coinfected with Hookworm & A. lumbricoides, A. lumbricoides & S. mansoni and A. lumbricoides & T. trichiura, respectively. Conclusions: The high prevalence of intestinal schistosomiasis and soil-transmitted helminthiasis observed in the study area shows the need of integrated control programme including periodic deworming, improving sanitation and access to clean water, appropriate health education and environmental measures to have a lasting impact on transmission.

Objective To determine incidence of hypercalcemia among TB patients with and without HIV infection before and after anti-TB chemotherapy in tropical settings of Northwest Ethiopia. Methods Serum levels of calcium were determined using an inductively coupled plasma mass spectrometer from all subjects at baseline and from 60 TB patients (34 with HIV co-infection) at the end of an intensive phase of anti-TB chemotherapy. Results At baseline, significant difference was found between the mean albumin-adjusted calcium levels in TB patients with HIV (11.95±3.72) and controls (9.81±1.59) (P=0.03). Hypercalcemia (serum calcium of > 10.5 mg/dL) was observed in 62.2% and 43.2% of TB patients with and without HIV co-infection, respectively. The serum levels of calcium did not significantly change after anti-TB chemotherapy both in patients with (n = 34) and without (n = 26) HIV co-infection. Conclusions The present study suggests that TB itself appears not to be responsible for hypercalcemia; however, rates of hypercalcemia are high in TB and HIV co-infected patients in the tropical settings of Northwest Ethiopia, of rarely symptomatic. Anti-TB chemotherapy does not improve the incidence of hypercalcemia in both groups with HIV co-infection and without.